Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncology Pharma Inc ONPH

Healthcare Biotechnology
Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Company’s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Company’s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.


GREY:ONPH - Post by User

Oncology Pharma Inc > ValiRx and TheoremRx - VAL201 - US$61M plus royalties
<< Previous
 Bullboard Posts
User Avatar Image
(0)
•••
Comment by Oldbaldyon Oct 22, 2023 8:47am
40 Views
Post# 35695171

RE:ValiRx and TheoremRx - VAL201 - US$61M plus royalties

RE:ValiRx and TheoremRx - VAL201 - US$61M plus royalties So is there any truth in this....?
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities